TRACK-HD: Both promise and disappointment

The Lancet Neurology

Volumn 11, Issue 1, 2012, Pages 24-25

  Kieburtz, Karl ^a   Venuto, Charles ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR; COGNITION; DISEASE COURSE; FUNCTIONAL STATUS; GENE MUTATION; GENETIC RISK; HUMAN; HUNTINGTON CHOREA; LETTER; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RATING SCALE; UNIFIED HUNTINGTON DISERASE RATING SCALE;

BRAIN; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE;

EID: 83555174444     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70285-X     Document Type: Letter

References (9)

1. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
2. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372. Huntington Study Group.
3. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008, 65:1582-1589. Huntington Study Group TREND-HD Investigators.
4. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011, 10:1049-1057.
5. Tabrizi SJ, Scahill RI, Durr A, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2011, published online Dec 2. 10.1016/S1474-4422(11)70263-0.
6. Tabrizi SJ, Reilmann R, Roos RAC, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011, 10:31-42.
7. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008, 79:874-880.
8. At risk for Huntington disease: the PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol 2006, 63:991-996. Huntington Study Group PHAROS Investigators.
9. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006, 66:628-633.